Under the rubric of tumor immunity, SLC13A3 activates the NRF2-SLC7A11 pathway by taking up itaconic acid, thereby conferring resistance to ferroptosis in tumor cells and reducing the efficacy of immune checkpoint blockade (ICB) therapy. Here, SLC13A3 is linked to neoplasm.